Skip to main content

Table 1 Participant characteristics (N = 23)

From: Lynch syndrome: barriers to and facilitators of screening and disease management

ID Family Gender Post-GT a Age b Affected Onset Age Cancer Types c
23 1B Female 6.42 57 No --- ---
24 1B Female 6.42 78 Yes 46 CRC/EC
25 1B Male 8.50 52 Yes 42 CRC/GA
26 1B Female 2.42 32 No --- ---
31 1B Male 7.50 47 Yes 45 CRCx2
8 1C Male 3.67 28 No --- ---
22 1C Male 6.50 26 No --- ---
30 1C Male 7.42 57 No --- ---
9 2A Female 8.08 41 Yes 39 CRCx2
32 2A Female 9.58 69 Yes 35 CRCx2/EC/GA/SK
20 2B Female 9.08 50 Yes 33 EC/BR/VA
21 2C Male 9.08 50 No --- ---
10 3A Female 7.00 42 No --- ---
27 3A Female 8.17 51 Yes 43 Ovarian
28 3A Male 8.17 43 Yes 45 CRC/DUO
29 3A Female 7.50 33 No --- ---
11 3B Male 8.42 76 Yes 39 CRCx2/SK/KD
4 6 Female 0.75 48 Yes 49 CRC
19 6 Female 0.08 63 Yes 54 SK
37 7 Female 3.17 50 Yes 46 KD/EC
38 7 Male 3.08 46 No --- ---
34 8 Female 2.83 43 Yes 40 EC
36 8 Female 3.75 42 No --- ---
  1. Note. Families 1B to 3B have the intron 5 mutation and families 6 to 8 have the exon 8 deletion. The use of A, B or C after the family number denotes separate nuclear families within a particular extended family.
  2. a Years since genetic testing.
  3. b Age at first interview.
  4. c CRC = colorectal; EC = endometrial; GA = gastric; SK = skin; BR = breast; VA = vaginal;
  5. KD = kidney; DUO = duodenal.